May 2021 in “The journal of investigative dermatology/Journal of investigative dermatology” This research discusses a zebrafish model showing that nicastrin deficiency leads to tyrosinase-dependent depigmentation and melanophore cell death, suggesting implications for studying skin depigmentation disorders.
16 citations
,
September 1999 in “Journal of Investigative Dermatology Symposium Proceedings” 3 citations
,
October 2024 in “Cancers” In this study, 37.5% of patients with nodal or metastatic cutaneous melanoma treated with immune checkpoint inhibitors developed skin adverse events, primarily low-grade rashes, vitiligo, and other dermatological symptoms, occurring mainly after 10 weeks of treatment.
25 citations
,
May 2018 in “Clinical & Translational Oncology” This review summarizes common skin-related side effects of BRAF inhibitors and immunotherapy in advanced melanoma treatment, reporting no new clinical findings, and emphasizes consensus management to improve patient outcomes.
21 citations
,
February 2013 in “Clinics in Dermatology” This review discusses recent developments in targeted melanoma therapies, including BRAF/MEK/ERK pathway inhibitors and challenges like resistance and skin toxicities, but reports no new clinical results.